Close

Jefferies Reiterates Buy Rating on Veru, Inc. (VERU), Upside DCF PT $98

Go back to Jefferies Reiterates Buy Rating on Veru, Inc. (VERU), Upside DCF PT $98

Brookline Capital Markets Reiterates Buy Rating on Veru, Inc. (VERU), PT $31

July 6, 2022 4:30 PM EDT

Brookline Capital Markets analyst Kumaraguru Raja reiterated a Buy rating and $31.00 price target on Veru, Inc. (NASDAQ: VERU)

The analyst comments "Results of the Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin, for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute... More

Veru, Inc. (VERU) Adds to Earlier Gain, Up 17% Afterhours

July 6, 2022 4:21 PM EDT

Veru, Inc. (NASDAQ: VERU) Adds to Earlier Gain, Up 17% Afterhours

... More

Veru, Inc. (VERU) Extends Gain, Now Up 20%

July 6, 2022 9:54 AM EDT

Veru, Inc. (NASDAQ: VERU) Extends Gain, Now Up 20%

... More

Veru (VERU) Climbs 7% After Publication of Phase 3 Data on Sabizabulin

July 6, 2022 7:33 AM EDT

Veru, Inc. (NASDAQ: VERU) Climbs 7% After Reporting Publication of Phase 3 Data Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

... More

Veru, Inc. (VERU) Reports Publication of Phase 3 Data Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

July 6, 2022 7:31 AM EDT

Veru Inc. (NASDAQ: VERU) today announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death in The New England Journal of Medicine (NEJM)... More